

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/010180 A1

(51) International Patent Classification⁷: **C07H 21/02**,
21/04, A61K 31/70, A01K 67/00

(74) Agent: **FIELD, Bret, E.**; Bozicevic, Field & Francis,
L.L.P, 200 Middlefield Road, Suite 200, Menlo Park, CA
94025 (US).

(21) International Application Number: PCT/US02/22869

(81) Designated States (*national*): AU, CA, JP.

(22) International Filing Date: 19 July 2002 (19.07.2002)

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, SK, TR).

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(30) Priority Data:
60/307,411 23 July 2001 (23.07.2001) US
60/360,664 27 February 2002 (27.02.2002) US

(71) Applicant: **THE BOARD OF TRUSTEES OF THE LE-
LAND STANFORD JUNIOR UNIVERSITY** [US/US];
900 Welch Road, Suite 350, Palo Alto, CA 94304 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors: **KAY, Mark**; 565 Casita Way, Los Altos, CA
94022 (US). **MCCAFFREY, Anton**; 77 Paloma, #204,
Pacifica, CA 94044 (US).



WO 03/010180 A1

(54) Title: METHODS AND COMPOSITIONS FOR RNAI MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS

(57) Abstract: Methods and compositions are provided for modulating, e.g., reducing, coding sequence expression in mammals. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is administered to a non-embryonic mammal, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.

